Skip to main content
. 2020 Oct 23;28(5):2632–2645. doi: 10.1245/s10434-020-09214-x

Fig. 5.

Fig. 5

The DOR of the nomogram to predict the pathological outcomes of NCT in the (a) training cohort and (b) validation cohort at different cut-off values. DOR diagnostic odds ratio, NCT neoadjuvant chemotherapy